checkAd

    DGAP-News  281  0 Kommentare XPhyto Therapeutics Corp.: XPhyto Adds Mescaline Production to Psychedelic Medicine Programs - Seite 3

    Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.

    SOURCE: XPhyto Therapeutics Corp.


    10.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.dgap.de

    Lesen Sie auch

    1167260  10.02.2021 

    fncls.ssp?fn=show_t_gif&application_id=1167260&application_name=news&site_id=wallstreet
    Seite 3 von 3


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    DGAP-News XPhyto Therapeutics Corp.: XPhyto Adds Mescaline Production to Psychedelic Medicine Programs - Seite 3 DGAP-News: XPhyto Therapeutics Corp. / Key word(s): Miscellaneous XPhyto Therapeutics Corp.: XPhyto Adds Mescaline Production to Psychedelic Medicine Programs 10.02.2021 / 09:05 The issuer is solely responsible for the content of this …